22741-52-2

Usage

Uses

Used in Pharmaceutical Industry:
3-(tert-butylamino)propane-1,2-diol is utilized as a chiral auxiliary in organic synthesis, playing a crucial role in controlling the stereochemistry of reactions. This ensures the production of specific enantiomers, which is vital for the development of effective and safe pharmaceuticals, as different enantiomers can have distinct biological activities.
Used in Organic Synthesis:
As a chiral auxiliary, 3-(tert-butylamino)propane-1,2-diol is employed to guide the stereoselectivity of chemical reactions, leading to the formation of desired enantiomers with high selectivity. This is particularly important in the synthesis of complex organic molecules and natural products.
Used in Drug Delivery Systems:
3-(tert-butylamino)propane-1,2-diol has been studied for its potential as a drug delivery agent due to its ability to form stable complexes with a variety of drugs. This property allows for improved drug solubility, enhanced bioavailability, and targeted drug delivery, which can lead to more effective treatments with reduced side effects.
Used in Resolving Enantiomeric Mixtures:
3-(tert-butylamino)propane-1,2-diol can also be used as a resolving agent for enantiomeric mixtures, enabling the separation of enantiomers and the production of pure enantiomers for pharmaceutical applications. This is essential for ensuring the safety and efficacy of chiral drugs, as the biological activity and pharmacokinetics of enantiomers can differ significantly.

InChI:InChI=1/C7H17NO2/c1-7(2,3)8-4-6(10)5-9/h6,8-10H,4-5H2,1-3H3

Upstream product

• 6387-89-9 glycidyl acetate 
• 75-64-9 tert-butylamine 
• 556-52-5 oxiranyl-methanol 
• 4042-36-8 D-pyrrolidone-5-carboxylic acid 
• 98-79-3 L-Pyroglutamic acid 
• 74924-01-9 (DL)-2,2-dimethyl-4-((tert-butylamino)methyl)-1,3-dioxolane 

Downstream Products

• 90531-69-4 Diphenyl-acetic acid 3-tert-butylamino-2-hydroxy-propyl ester 
• 83231-29-2 4-Hydroxy-benzoic acid 3-tert-butylamino-2-hydroxy-propyl ester 
• 83231-16-7 4-Formyl-benzoic acid 3-tert-butylamino-2-hydroxy-propyl ester 
• 30315-49-2 3-tert-butyl-2-phenyl-5-hydroxymethyloxazolidine 
• 83231-02-1 Benzoic acid 3-tert-butylamino-2-hydroxy-propyl ester 
• 83231-09-8 4-Nitro-benzoic acid 3-tert-butylamino-2-hydroxy-propyl ester 
• 83231-06-5 2-Methyl-benzoic acid 3-tert-butylamino-2-hydroxy-propyl ester 
• 90531-68-3 4-Phenyl-butyric acid 3-tert-butylamino-2-hydroxy-propyl ester 
• 90531-57-0 2-Chloro-4-nitro-benzoic acid 3-tert-butylamino-2-hydroxy-propyl ester 
• 83231-04-3 2-Fluoro-benzoic acid 3-tert-butylamino-2-hydroxy-propyl ester 
• 90531-66-1 Phenyl-acetic acid 3-tert-butylamino-2-hydroxy-propyl ester 
• 90531-67-2 3-Phenyl-propionic acid 3-tert-butylamino-2-hydroxy-propyl ester 
• 83231-08-7 3-Nitro-benzoic acid 3-tert-butylamino-2-hydroxy-propyl ester 
• 83231-07-6 3-Methyl-benzoic acid 3-tert-butylamino-2-hydroxy-propyl ester 

Relevant academic research and scientific papers

Ophthalmic compositions and their use for treating elevated intraocular pressure and glaucoma

Antiglaucoma compositions that contain enriched R-(+)-1-tert-butylamino-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol compared to the S-(-)-isomer and the ophthalmologically acceptable acid addition salts thereof are useful in methods for treating glaucoma and elevated intraocular pressure.

propanolamines. 1. Novel β-Blockers with Ultrashort Duration of Action

Novel propanolamines were synthesized and investigated as potential ultrashort-acting β-adrenergic receptor blockers.Many of these analogues exhibited good potency and short duration.The N-ureidoalkyl analogue 85 (ACC-9089) has a potency equal to propranolol and a duration of action of about 21 min in the dog.It has been selected as a candidate for further clinical study.Structure-activity relationships and structure-duration relationships for these new β-blockers are also discussed.

Total Synthesis of (R)-Glycerol Acetonide and the Antiepileptic and Hypotensive Drug (-)-γ-Amino-β-hydroxybutyric Acid (GABOB): Use of Vitamin C as a Chiral Starting Material

Ascorbic acid (Vitamin C) (9) is shown to be a useful, inexpensive chiral starting material for natural products synthesis.It is converted in high yield via two synthetic operations into (R)-glycerol acetonide (7), the more inaccessible enantiomer of glycerol acetonide.Since D-(R)-glyceraldehyde acetonide (4) and the corresponding alcohol 1 have been used in many total syntheses of a wide variety of compounds, the ready availability of the opposite enantiomers L-(S)-glyceraldehyde acetonide (6) and glycerol (7) should be of greate value.As one indication of this potential synthetic utility, the hypotensive, antiepileptic compound (R)-(-)-γ-amino-β-hydroxybutyric acid (GABOB) (8) has been synthesized from ascorbic acid (9) via nine steps in 10percent overall yield.As further evidence of the importance of these synthesis, several useful intermediates for the preparation of the highly active hypotensive agents, the aryloxypropanolamines (5), were prepared from Vitamin C.

Synthesis and β-Adrenergic Blocking Activity of New Aliphatic Oxime Ethers

New β-adrenergic blocking agents, most of which do not contain an aromatic nucleus, were synthesized.They were derived either from alkylamino-aliphatic oxime ethers, or alkylamino-aliphatic ethers.Most active among these are O-acetoxime (8; trachea pA2=7.65) and 1-isobutoxy-3-(tert-butylamino)-2-propanol (15, trachea pA2=7.49), both of which displayed bronchoselectivity (β2/β1 ratio ca. 15).The role and importance of the aromatic nucleus in this class of compounds are discussed

Pyroglutamic acid salts of t-butylamino-2,3-dihydroxypropane

Process for resolving enantiomers of 1-t-butylamino-2,3-dihydroxypropane using a pyroglutamic acid or a tartaric acid as resolving agent. The enantiomers of 1-t-butylamino-2,3-dihydroxypropane are useful in preparing β-adrenergic blocking agents.

Certain 1-amino-3-(1-isoquinolinyl)oxy-2-propanol derivatives

This invention provides compounds of formula I, STR1wherein R is alkyl of 3 to 7 carbon atoms; cycloalkyl of 3 to 7 carbon atoms; cycloalkyl of 3 to 7 carbon atoms monosubstituted with alkyl of 1 to 4 carbon atoms; α-dialkylpropinyl of 5 to 9 carbon atoms; α-dialkylallyl of 5 to 9 carbon atoms; hydroxyalkyl of 2 to 7 carbon atoms, the hydroxy group thereof being separated by at least two carbon atoms from the nitrogen atom to which R is bound; phenethyl; phenethyl mono- or disubstituted in the phenyl residue independently when di-substituted with halogen of atomic number from 9 to 35, alkyl of 1 to 4 carbon atoms or unbranched alkoxy of 1 to 4 carbon atoms; or adamantyl; and Either R1 is phenyl and R2 is hydrogen; Or R1 is alkyl of 1 to 4 carbon atoms or halogen of atomic number from 9 to 35 and R2 is unbranched alkoxy of 1 to 4 carbon atoms or halogen of atomic number from 9 to 35, with the general proviso that the 8-position of the isoquinoline is unsubstituted and any halogen substituent which may be present in the 3- or 4- position is other than fluorine, Useful for treating coronary diseases, arrhythmia, hyperlipoidemia and hyperglycemia.